The study analysed that the Herpes simplex virus infections pipeline comprises of 20 drug candidates in different stages of development.
As per the findings of the research, most of the drug candidates are being developed to be administered by oral route.
Request to Get the Sample [email protected] https://www.psmarketresearch.com/market-analysis/hsv-infections-therapeutics-pipeline-analysis/report-sample
Many technologies are being developed that offer promising innovative teatments which can control the progression of Herpes Simplex Virus infections. The technologies include, but not limited to, Vector based technology platform, AdenoVerse technology platform, Juvari’s technology platform and Nanostat technology platform.
Explore Full Report Description [email protected] https://www.psmarketresearch.com/market-analysis/hsv-infections-therapeutics-pipeline-analysis
Herpes Simplex Virus Infections Therapeutics Pipeline Analysis
- By Phase
- By Route of Administration
- By Molecule Type
- By Company
The research found that various companies have collaborated for the development of Herpes Simplex Virus Infections pipeline. In June 2014, PaxVax Inc., entered into a research and development collaboration with the University of California to develop a combination vaccine to prevent genital herpes simplex virus infections.
Some of the key players developing drugs for the treatment of Herpes virus simplex infections include Maruho Co., Ltd., NanoBio Corporation, Lumavita AG and others.
About P&S Intelligence
P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.
P&S Market Research
347, 5th Ave. #1402
New York City, NY – 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: [email protected]
Connect with us: LinkedIn | Twitter | Google + | Facebook
, Research Newswire, Press Release, North America, United States, Europe, Asia, Middle East, English